{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:27:15Z","timestamp":1793791635705,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biopha.2024.116331","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:09:11Z","timestamp":1709251751000},"page":"116331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-1513","authenticated-orcid":false,"given":"An-Na","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-6252","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Breyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-7631","authenticated-orcid":false,"given":"Dong-Keun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R\u00f8nn","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-9635","authenticated-orcid":false,"given":"Keonwoo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonsuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-7433","authenticated-orcid":false,"given":"Wan","family":"Namkung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.116331_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100525","article-title":"The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes","author":"Younossi","year":"2022","journal-title":"JHEP Rep."},{"issue":"5","key":"10.1016\/j.biopha.2024.116331_bib3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.biopha.2024.116331_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116331_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2024.116331_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2024.116331_bib7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"issue":"10215","key":"10.1016\/j.biopha.2024.116331_bib9","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.biopha.2024.116331_bib10","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"issue":"Suppl","key":"10.1016\/j.biopha.2024.116331_bib13","first-page":"1257A","article-title":"MET409, a sustained FXR agonist, decreased hepatic fat and improved liver function without raising LDL-C after 28 days in NASH patients","volume":"70","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116331_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and fatty liver disease\u2014the known, the unknown, and the future","volume":"28","author":"Lang","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.116331_bib18","unstructured":"Moon A.-N., Lee Y., Song D.--K., Briand F. ID119031166, A Novel Potent Non-bile acid FXR Agonist, Improves NASH and Liver Fibrosis Without Plasma LDL-C Elevation in a Diet-induced Obese NASH Hamster Model. In.HEPATOLOGY: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2022. p. S611-S611."},{"issue":"7887","key":"10.1016\/j.biopha.2024.116331_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2024.116331_bib20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2015.1045413","article-title":"Farnesoid X receptor modulators (2011\u20132014): a patent review","volume":"25","author":"Sepe","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"issue":"19","key":"10.1016\/j.biopha.2024.116331_bib21","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","article-title":"Knocking on FXR\u00b4 s Door: The","volume":"14","author":"Gege","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2024.116331_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejphar.2017.11.021","article-title":"Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model","volume":"818","author":"Briand","year":"2018","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2024.116331_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.biopha.2024.116331_bib24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116331_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1248\/bpb.24.579","article-title":"The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals","volume":"24","author":"Tsutsumi","year":"2001","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib26","article-title":"NASH-related increases in plasma bile acid levels depend on insulin resistance","volume":"3","author":"Grzych","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2024.116331_bib27","first-page":"534","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","author":"Puneet","year":"2018","journal-title":"In"},{"issue":"4","key":"10.1016\/j.biopha.2024.116331_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1440-1746.2010.06522.x","article-title":"Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease","volume":"26","author":"Eisendle","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"21","key":"10.1016\/j.biopha.2024.116331_bib29","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116331_bib30","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2024.116331_bib31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.116331_bib32","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","author":"Xu","year":"2022","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2024.116331_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.biopha.2024.116331_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000127","article-title":"FXR and NASH: an avenue for tissue-specific regulation","volume":"7","author":"Henry","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2024.116331_bib36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin. Transl. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116331_bib37","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.116331_bib38","unstructured":"Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects. In.: \u3008https:\/\/classic.clinicaltrials.gov\/show\/NCT05604287\u3009."},{"issue":"9","key":"10.1016\/j.biopha.2024.116331_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/acsmedchemlett.3c00001","article-title":"Trust your gut: strategies and tactics for intestinally restricted drugs","volume":"14","author":"Dorel","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2024.116331_bib41","article-title":"The gut microbiota\u2013bile acid axis: a potential therapeutic target for liver fibrosis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2024.116331_bib43","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J. Dig. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"6","key":"10.1016\/j.biopha.2024.116331_bib45","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2024.116331_bib46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116331_bib47","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.24978","article-title":"Claudins in intestines: distribution and functional significance in health and diseases","volume":"1","author":"Lu","year":"2013","journal-title":"Tissue Barriers"},{"issue":"2","key":"10.1016\/j.biopha.2024.116331_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ajpath.2011.10.025","article-title":"Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function","volume":"180","author":"Patel","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116331_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.04439.x","article-title":"Tight junction proteins as channel formers and barrier builders: claudin-2,-5, and-8","volume":"1165","author":"Amasheh","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2024.116331_bib50","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/hep4.1428","article-title":"Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of Low-Density lipoprotein cholesterol","volume":"3","author":"Labenz","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2024.116331_bib51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat. Med."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:44:56Z","timestamp":1793789096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224002154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S0753332224002154"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116331","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116331"}}